Limits...
Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma.

Corrias MV, Parodi S, Haupt R, Lacitignola L, Negri F, Sementa AR, Dau D, Scuderi F, Carlini B, Bianchi M, Casale F, Faulkner L, Garaventa A - Br. J. Cancer (2008)

Bottom Line: GD2 positivity was not associated to other known risk factors, and in particular to Myc-N amplification and 1p deletion.Among Myc-N-negative patients, the EFS of those negative for both GD2 and 1p deletion was significantly better than in children positive for either one of these two markers (EFS=96.9 vs 66.0%, P<0.001).In conclusion, GD2 positivity may represent a prognostic marker for patients with non-metastatic NB without Myc-N amplification, and its combination with genetic alterations might help identifying patients that require a more careful follow-up.

View Article: PubMed Central - PubMed

Affiliation: Department of Experimental and Laboratory Medicine, Laboratory of Oncology, Gaslini Institute, Largo Gaslini, 5, Genoa 16147, Italy. mariavaleriacorrias@ospedale-gaslini.ge.it

ABSTRACT
The impact of bone marrow (BM) GD2-positive cells on survival has been evaluated in 145 Italian children with localised neuroblastoma (NB) evaluated at diagnosis by anti-GD2 immunocytochemistry. Nineteen of these (13.1%) were found to be BM GD2-positive, with the number of positive cells ranging between 1 and 155 out of 1 x 10(6) total cells analysed. Seven/19 (38.8%) GD2-positive vs 12/126 (9.5%) GD2-negative patients relapsed. The 5-year event-free survival (EFS) and overall survival of the GD2-positive patients was significantly worse than that of the GD2-negative ones (62.2 vs 89.9%, P<0.001; and 74.9 vs 95.9%, P=0.005, respectively). GD2 positivity was not associated to other known risk factors, and in particular to Myc-N amplification and 1p deletion. Among Myc-N-negative patients, the EFS of those negative for both GD2 and 1p deletion was significantly better than in children positive for either one of these two markers (EFS=96.9 vs 66.0%, P<0.001). In conclusion, GD2 positivity may represent a prognostic marker for patients with non-metastatic NB without Myc-N amplification, and its combination with genetic alterations might help identifying patients that require a more careful follow-up.

Show MeSH

Related in: MedlinePlus

Cytospin of BM aspirates fixed in acetone and immunologically stained with anti-GD2 antibody. (A, B) Rosettes of NB cells stained in red, from patients F/18 and F/8, respectively; (C) a single NB cell stained in red from patient M/73; (D) a completely negative aspirate. Magnification is × 40.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2361437&req=5

fig1: Cytospin of BM aspirates fixed in acetone and immunologically stained with anti-GD2 antibody. (A, B) Rosettes of NB cells stained in red, from patients F/18 and F/8, respectively; (C) a single NB cell stained in red from patient M/73; (D) a completely negative aspirate. Magnification is × 40.

Mentions: Demographic, clinical, biochemical and genetic features of the 145 study patients stratified according to BM GD2-IC status are reported in Table 1. In more detail, 126 patients (86.9%) were GD2 negative and 19 (13.1%) were GD2 positive. Among the 19 GD2-positive patients (Table 2), the number of positive cells ranged between 1 and 155 (median=3; IQR 2-20) out of 106 total cells examined. It is to be noted that of the 11 patients with less than five GD2-positive cells/106 total cells, seven were also evaluated by RT-PCR and all but one were found to be positive for at least one NB molecular marker (data not shown). Three examples of GD2-positive samples are shown in Figure 1. As reported in Table 1, no association was found between GD2 status and each of the other risk factors considered.


Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma.

Corrias MV, Parodi S, Haupt R, Lacitignola L, Negri F, Sementa AR, Dau D, Scuderi F, Carlini B, Bianchi M, Casale F, Faulkner L, Garaventa A - Br. J. Cancer (2008)

Cytospin of BM aspirates fixed in acetone and immunologically stained with anti-GD2 antibody. (A, B) Rosettes of NB cells stained in red, from patients F/18 and F/8, respectively; (C) a single NB cell stained in red from patient M/73; (D) a completely negative aspirate. Magnification is × 40.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2361437&req=5

fig1: Cytospin of BM aspirates fixed in acetone and immunologically stained with anti-GD2 antibody. (A, B) Rosettes of NB cells stained in red, from patients F/18 and F/8, respectively; (C) a single NB cell stained in red from patient M/73; (D) a completely negative aspirate. Magnification is × 40.
Mentions: Demographic, clinical, biochemical and genetic features of the 145 study patients stratified according to BM GD2-IC status are reported in Table 1. In more detail, 126 patients (86.9%) were GD2 negative and 19 (13.1%) were GD2 positive. Among the 19 GD2-positive patients (Table 2), the number of positive cells ranged between 1 and 155 (median=3; IQR 2-20) out of 106 total cells examined. It is to be noted that of the 11 patients with less than five GD2-positive cells/106 total cells, seven were also evaluated by RT-PCR and all but one were found to be positive for at least one NB molecular marker (data not shown). Three examples of GD2-positive samples are shown in Figure 1. As reported in Table 1, no association was found between GD2 status and each of the other risk factors considered.

Bottom Line: GD2 positivity was not associated to other known risk factors, and in particular to Myc-N amplification and 1p deletion.Among Myc-N-negative patients, the EFS of those negative for both GD2 and 1p deletion was significantly better than in children positive for either one of these two markers (EFS=96.9 vs 66.0%, P<0.001).In conclusion, GD2 positivity may represent a prognostic marker for patients with non-metastatic NB without Myc-N amplification, and its combination with genetic alterations might help identifying patients that require a more careful follow-up.

View Article: PubMed Central - PubMed

Affiliation: Department of Experimental and Laboratory Medicine, Laboratory of Oncology, Gaslini Institute, Largo Gaslini, 5, Genoa 16147, Italy. mariavaleriacorrias@ospedale-gaslini.ge.it

ABSTRACT
The impact of bone marrow (BM) GD2-positive cells on survival has been evaluated in 145 Italian children with localised neuroblastoma (NB) evaluated at diagnosis by anti-GD2 immunocytochemistry. Nineteen of these (13.1%) were found to be BM GD2-positive, with the number of positive cells ranging between 1 and 155 out of 1 x 10(6) total cells analysed. Seven/19 (38.8%) GD2-positive vs 12/126 (9.5%) GD2-negative patients relapsed. The 5-year event-free survival (EFS) and overall survival of the GD2-positive patients was significantly worse than that of the GD2-negative ones (62.2 vs 89.9%, P<0.001; and 74.9 vs 95.9%, P=0.005, respectively). GD2 positivity was not associated to other known risk factors, and in particular to Myc-N amplification and 1p deletion. Among Myc-N-negative patients, the EFS of those negative for both GD2 and 1p deletion was significantly better than in children positive for either one of these two markers (EFS=96.9 vs 66.0%, P<0.001). In conclusion, GD2 positivity may represent a prognostic marker for patients with non-metastatic NB without Myc-N amplification, and its combination with genetic alterations might help identifying patients that require a more careful follow-up.

Show MeSH
Related in: MedlinePlus